F-star Therapeutics, Inc.: F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research

- FS118 is Well-Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and LAG-3 shedding - 54.8%

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Texas ,American ,John Fraunces ,Louis Kayitalire ,Timothya Yap ,Linkedin ,Sino Biopharmaceutical ,Fennec Acquisition Incorporated ,University Of Texas Md Anderson Cancer Center ,Twitter ,Innisfree Ma Incorporated ,Nasdaq ,American Association For Cancer Research ,Therapeutics Inc ,Securities Exchange ,Globe Newswire Therapeutics Inc ,X Biopharm ,Clinical Cancer Research ,Well Tolerated Across ,Dose Levels ,Increased Peripheral Immune Cells ,Disease Control Rate ,Resistance Patients ,Anaplastic Thyroid ,Acquired Resistance Squamous Cell Carcinoma ,American Association ,Chief Medical Officer ,F Star Therapeutics ,Sino Biopharmaceutical Limited ,Recommendation Statement ,Information Agent ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Quarterly Reports ,Life Science ,Star ,Herapeutics ,Nnounces ,Publication ,Hase ,Nose ,Escalation ,Trial ,Fs118 ,Patients ,Dvanced ,Dancer ,Resistance ,Linical ,Research ,